Navigation Links
Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia
Date:1/28/2016

TUSCALOOSA, Ala., Jan. 28, 2016 /PRNewswire/ -- Innovative Med Concepts, LLC, announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the development of IMC-1 for the treatment of fibromyalgia.  IMC-1 previously completed a randomized, double-blinded, placebo controlled Phase II study (PRID-201), showing that IMC-1 appears to have promise treating the pain and other symptoms of fibromyalgia.

Logo - http://photos.prnewswire.com/prnh/20160128/326954

William Pridgen, M.D., Founder and CEO of Innovative Med Concepts, stated,  "We are pleased that the FDA has granted Fast Track status to IMC-1, as it demonstrates their recognition of this condition as a significant unmet medical need.  IMC-1 has a novel mechanism of action designed to suppress chronic tissue-resident herpes virus, which may have a role in triggering or maintaining symptoms of fibromyalgia.  IMC-1 is a fixed-dose combination using proprietary doses of famciclovir, an anti-viral nucleoside analog, and celecoxib, a COX-2 inhibitor that also possesses unique anti-viral activity.  Suppressing latent herpes viruses may significantly improve fibromyalgia related symptoms.  We are currently meeting the development requirements to begin Phase III trials with IMC-1 in 2017."

Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious diseases.  In order to receive Fast Track designation, a product must demonstrate the potential to address an unmet medical need in a serious condition.  Companies granted Fast Track designation benefit from greater access to, and more frequent communications with, the FDA throughout the drug development or review process and are allowed to submit New Drug Applications (NDA) on a rolling basis.  In addition, Fast Track designation products are eligible for potential accelerated approval and priority review.

About Fibromyalgia

Fibromyalgia is a debilitating disorder involving widespread chronic pain along with other symptoms of fatigue, headaches, sleep problems, mood changes and inability to concentrate.  According to the National Fibromyalgia Association, an estimated 3-6 percent of people worldwide suffer from the condition, or approximately 10 million in the United States and 220 million worldwide.

About Innovative Med Concepts

Innovative Med Concepts, LLC, is a biotech company developing novel treatments for fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), irritable bowel syndrome and other related conditions. On the Web: http://innovativemedconcepts.com.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "projects," "expects," "may," "intends," "will," "should," or "anticipates" or the negative thereof or similar terminology. These statements appear in a number of places in this press release and include statements regarding IMC's or its management's intent, belief, or current expectations with respect to, among other things: IMC's regulatory approvals and future clinical trials, financial projections regarding IMC's future financial performance and condition, trends affecting IMC's financial condition and results of operations, and IMC's business and growth strategies. Forward-looking statements are subject to risks, uncertainties, and assumptions about IMC.

In light of these risks, uncertainties, and assumptions, IMC can give no assurance that the events disclosed in the forward-looking statements in this press release will in fact transpire. IMC undertakes no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events, or otherwise. IMC expressly disclaims any representation regarding any forward-looking statements. All forward-looking statements in this press release are expressly qualified by the foregoing cautionary statements. 

Innovative Med Concepts Contact:

Rick Burch

President

rick@innovativemedconcepts.com

 


'/>"/>
SOURCE Innovative Med Concepts, LLC
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. WuXi and AstraZeneca Form Strategic Alliance to Expedite Development of AstraZenecas Innovative Biologics Portfolio in China
2. Gulf Coast Tech Company, iViews Imaging System, LLC, Provides Innovative Software Solutions For Eye Care Professionals and Introduces A New Cloud Based Co-ManagemenSystem
3. 2016 Europe Cell Surface Markers: Country Volume and Sales Forecasts, Innovative Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, Italy, Spain, UK
4. Global Molecular Diagnostics Market 2016-2021 - Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies
5. United States Molecular Blood Typing, Grouping and Infectious Disease NAT Market 2015-2019 - Supplier Shares, Sales Forecasts, Innovative Technologies, Competitive Strategies
6. Phononic Wins Innovative Product Award at 2015 NC Tech Awards
7. Svigals+Partners Announces Completion of Innovative Facility for Children’s Brain Research at UConn
8. An innovative sample management partnership with the Crohns & Colitis Foundation is advancing precision medicine through novel research to find a cure for IBD
9. United States Cell Surface Marker Testing Market 2015: Competitive Strategies, Country Forecasts, Innovative Technologies, Emerging Opportunities
10. Sigma-Aldrich Announces Strategic Collaboration with UC San Franciscos Catalyst Program to Accelerate Commercialization of Innovative Research Tools
11. CTI BioPharma And Fred Hutchinson Cancer Research Center Announce International Research Fellowship To Support Innovative Blood-Related Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...
(Date:10/7/2017)... Seattle, WA (PRWEB) , ... ... ... the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome ... the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):